Dual inhibitors of SWI/SNF catalytic subunits, BRM (SMARCA2) and BRG1 (SMARCA4) lead to downregulation of leukemic pathway genes, including MYC in AML cell lines [208]. Here, SMARCA1 is linked to acute myeloid leukemia.